Patients with BRCA1 or BRCA2-mutated metastatic breast cancer might benefit from treatment with lurbinectedin—a selective inhibitor of active transcription of protein-coding genes—according to a recent study. ...
CONCLUSION: Lurbinectedin showed noteworthy activity in patients with BRCA1/2 mutations. Response and survival was notable in those with BRCA2 mutations. Additional clinical development in this subset of patients with metastatic breast cancer is warranted.